MX354752B - Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. - Google Patents
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.Info
- Publication number
- MX354752B MX354752B MX2013003238A MX2013003238A MX354752B MX 354752 B MX354752 B MX 354752B MX 2013003238 A MX2013003238 A MX 2013003238A MX 2013003238 A MX2013003238 A MX 2013003238A MX 354752 B MX354752 B MX 354752B
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant adenovirus
- malaria
- boosting composition
- subject
- adenovirus vector
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title abstract 5
- 238000002255 vaccination Methods 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 6
- 244000045947 parasite Species 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a el uso de (i) una composición de sensibilización que comprende un antígeno proteináceo con adyuvante que comprende proteína de circumsporozoito (CS) o una parte inmunogénica de la misma de un parásito causante de malaria; (ii) una primera composición de refuerzo que comprende un vector de adenovirus recombinante de Ad35 que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria; y (iii) una segunda composición de refuerzo que comprende un vector de adenovirus recombinante de Ad26 que comprende ácido nucleico que codifica proteína de CS o una parte inmunogénica de la misma de un parásito causante de malaria, para la manufactura de un medicamento para inducir una respuesta inmunológica en un sujeto contra un antígeno de un parásito causante de malaria, en donde dichas composiciones están adaptadas para ser administrables por separado a un sujeto, primero la composición de sensibilización, posteriormente la primera composición de refuerzo, y finalmente la segunda composición de refuerzo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40415610P | 2010-09-27 | 2010-09-27 | |
| EP10180251 | 2010-09-27 | ||
| PCT/EP2011/065434 WO2012041669A1 (en) | 2010-09-27 | 2011-09-07 | Heterologous prime boost vaccination regimen against malaria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003238A MX2013003238A (es) | 2013-05-30 |
| MX354752B true MX354752B (es) | 2018-03-20 |
Family
ID=43416881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003238A MX354752B (es) | 2010-09-27 | 2011-09-07 | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9168292B2 (es) |
| AU (1) | AU2011310838B2 (es) |
| BR (1) | BR112013004582A2 (es) |
| CA (1) | CA2809463C (es) |
| MX (1) | MX354752B (es) |
| WO (1) | WO2012041669A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2857087C (en) | 2011-11-28 | 2021-05-25 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| WO2015197820A1 (en) | 2014-06-26 | 2015-12-30 | Crucell Holland B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| EP3442570A1 (en) * | 2016-04-12 | 2019-02-20 | Oxford University Innovation Limited | Prime target |
| EP3941514A4 (en) * | 2019-03-20 | 2023-08-30 | Turnstone Biologics Inc. | ONCOLYTIC VIROTHERAPY BY HETEROLOGY SEQUENTIAL BOOSTER |
| WO2021041518A2 (en) * | 2019-08-27 | 2021-03-04 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| ATE177755T1 (de) | 1991-11-16 | 1999-04-15 | Smithkline Beecham Biolog | Hybrides protein zwischen cs aus plasmodium und hbsag |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| PT729473E (pt) | 1993-11-17 | 2001-02-28 | Deutsche Om Arzneimittel Gmbh | Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
| ES2278399T3 (es) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6005009A (en) | 1997-03-19 | 1999-12-21 | Duke University | Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| US6645495B1 (en) | 1997-08-29 | 2003-11-11 | Antigenics, Inc. | Compositions of saponin adjuvants and excipients |
| ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| ATE519855T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus des serotyps ad11 |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| DK1497440T3 (da) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| CA2496918A1 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| CA2502268A1 (en) * | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| US20050208078A1 (en) * | 2003-11-20 | 2005-09-22 | Hoffman Stephen L | Methods for the prevention of malaria |
| WO2004055187A1 (en) | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| NZ548495A (en) | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| ES2371175T3 (es) | 2004-10-14 | 2011-12-28 | Crucell Holland B.V. | Vacunas de sensibilización/refuerzo de malaria. |
| DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
-
2011
- 2011-09-07 MX MX2013003238A patent/MX354752B/es active IP Right Grant
- 2011-09-07 WO PCT/EP2011/065434 patent/WO2012041669A1/en not_active Ceased
- 2011-09-07 US US13/823,581 patent/US9168292B2/en not_active Expired - Fee Related
- 2011-09-07 BR BR112013004582A patent/BR112013004582A2/pt not_active Application Discontinuation
- 2011-09-07 CA CA2809463A patent/CA2809463C/en not_active Expired - Fee Related
- 2011-09-07 AU AU2011310838A patent/AU2011310838B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2809463C (en) | 2021-05-25 |
| WO2012041669A1 (en) | 2012-04-05 |
| US9168292B2 (en) | 2015-10-27 |
| BR112013004582A2 (pt) | 2016-09-06 |
| AU2011310838B2 (en) | 2015-11-05 |
| AU2011310838A1 (en) | 2013-03-28 |
| MX2013003238A (es) | 2013-05-30 |
| US20130216580A1 (en) | 2013-08-22 |
| CA2809463A1 (en) | 2012-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX354752B (es) | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. | |
| IL214460A0 (en) | Malaria prime/boost vaccines | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| WO2007027860A3 (en) | Adenoviral vector-based malaria vaccines | |
| EA200901060A1 (ru) | Новый способ и композиции | |
| WO2018193063A3 (en) | NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS | |
| MX2009010870A (es) | Vector adenoviral que codifica el antigeno de malaria. | |
| MX2014009845A (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
| SG156535A1 (en) | Recombinant viral-based malaria vaccines | |
| MX363529B (es) | Vesículas de membrana externa. | |
| WO2012047679A3 (en) | Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria | |
| WO2009025770A3 (en) | A heterologous prime-boost immunization regimen | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| MX2009000655A (es) | Vacunasd para malaria. | |
| EA201290675A1 (ru) | Вакцинные векторы и способы усиления иммунных ответов | |
| MX2014011713A (es) | Composiciones y procedimientos antipaludismo. | |
| WO2008086386A8 (en) | Adenoviral vector-based malaria vaccines | |
| EA201171347A1 (ru) | Комбинированная вакцина против кори и малярии | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| WO2010127420A9 (pt) | Sequências geneticamente modificadas de antígenos de plasmodium vivax | |
| WO2011133870A3 (en) | Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap) | |
| WO2008027414A3 (en) | Novel p. falciparum vaccine proteins and coding sequences | |
| Radošević et al. | The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert | |
| WO2008100142A3 (en) | Vaccine formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |